ALSO IN THIS MONTH'S ISSUE
Biotech Veteran Pushes New Science And Regulatory Change
Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.
Companies To Watch: Nido Biosciences
See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
Leadership Pressures: Causing An Imbalanced Organization
We all must do what’s best for our business, our teams (people), and ultimately the patient in a compliant manner. So, what happens if you prioritize one over the other?
Addressing The Uncertainties Of The IRA In Biopharma
In recent years, the biopharma industry has been anything but predictable. But the creation of the Inflation Reduction Act (IRA) of 2022 has added a new layer of uncertainty that reaches most corners of the industry.